Rapid systemic surge of IL-33 after severe human trauma: a prospective observational study

Overview of attention for article published in Molecular Medicine, March 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 tweeter

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 6 Mendeley

Summary Twitter Dimensions citations

So far, Dimensions has found 6 publications that cite this research output.

6

The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.

Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

Preprint in bioRxiv (March 2023)

Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine

Article in Cytokine (May 2022)

IL-33/ST2 Axis Protects Against Traumatic Brain Injury Through Enhancing the Function of Regulatory T Cells

Article in Frontiers in Immunology (March 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.